Access to sterile syringes among young drug injectors in Madrid and Barcelona and its association with risk behaviour

Acceso a jeringas estériles entre los jóvenes de Madrid y Barcelona que se inyectan drogas y su asociación con las prácticas de riesgo

María J. Bravo^a, Luis Royuela^b, Gregorio Barrio^c, Mª Teresa Brugal^d, Antònia Domingo^e, Luis de la Fuente^f  and Itínere Project Group*

^aCIBER Epidemiología y Salud Pública (CIBERESP)
^bEuropean Monitoring Centre for Drugs and Drug Addiction
^cDepartamento de Medicina Preventiva, Salud Pública e Historia de la Ciencia, Universidad Complutense de Madrid, Madrid, España ]]> ^dAgència de Salut Pública de Barcelona, Barcelona, España
^eInstitut Municipal d'Investigació Médica (IMIM), Barcelona, España
^fCentro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, España.

This research was financed primarily by the Fundación para Investigación y la Prevención del Sida en España (FIPSE 3035/99 - Foundation for AIDS Research and Prevention in Spain); the analysis was possible thanks to the support of the Ciber de Epidemiología y Salud Pública.

*Itínere Project Group: Rosario Ballesta, Francisco González, Francisco Bru, Yolanda Castellano, David Fernández, Daniel Lacasa, Eusebio Mejías, Montserrat Neira, José Pulido, Sofía Ruiz, Fernando Sánchez, Teresa C Silva y Fernando Vallejo.

Correspondence

ABSTRACT

Background and objective: To evaluate access to sterile syringes and its association with injection risk behaviour in Madrid and Barcelona. ]]> Materials and methods: Cross-sectional community study by computer-assisted personal interview in 465 young heroin injectors between 2001 and 2003.
Results: Some 4.2% had not obtained any free sterile syringes in the previous 12 months. In Madrid 32.1% had obtained all their sterile syringes free of charge (ASSF), versus 44.6% in Barcelona (p < 0.01). Not sharing (not using syringes used by someone else and not front/backloading) was associated with obtaining ASSF (OR = 1.69) and with sporadic injection (OR = 1.83). Not reusing one's own syringes was associated with the same two variables (OR = 4.02 and OR = 2.50, respectively).
Conclusions: Access to sterile syringes is very high in Madrid and Barcelona, although the two cities have different approaches. The acquisition of all syringes free of charge should be facilitated, especially among frequent injectors.

Palabras clave: Drug injection. Syringe exchange programmes. Risk behaviour. HIV.

RESUMEN

Objetivo: Evaluar el acceso a jeringas estériles y su asociación con prácticas de inyección de riesgo en Madrid y Barcelona.
Material y método: Estudio transversal en la comunidad de 465 jóvenes que se inyectan heroína, realizado entre 2001 y 2003, mediante entrevista asistida por ordenador.
Resultados: Un 4,2% no obtuvo jeringas estériles gratuitas en los últimos 12 meses. En Madrid, el 32,1% obtuvo todas las jeringas estériles gratis (TJEG), frente al 44,6% de Barcelona (p < 0,01). No compartir (no utilizar jeringas ajenas usadas o droga diluida en las usadas por otros) se asoció con obtener TJEG (odds ratio [OR] = 1,69) e inyectarse esporádicamente (OR = 1,83). No reutilizar las jeringas propias se asoció con las mismas variables (OR = 4,02 y OR = 2,50, respectivamente).
Conclusiones: En Madrid y Barcelona el acceso a jeringas estériles es muy elevado, aunque con modelos diferentes. Debe facilitarse la obtención de todas las jeringas estériles gratis, especialmente entre los jóvenes que se inyectan con mayor frencuencia.

Key words: Inyección de drogas. Programas de intercambio de jeringas. Conductas de riesgo. VIH.

Introduction

Over the last 15 years, a growing number of initiatives have facilitated the provision of sterile syringes to drug injectors in Spain, primarily syringe exchange programmes (SEPs) and subsidised sales in pharmacies. The SEPs have branched out to new locations¹, and some injectors obtain their supplies through these programmes and subsequently sell them² (satellite distributors - SDs)³. However, the development of the SEPs has not been geographically homogeneous: in 2003 there were 254 SEPs with 1,560 exchange points (EPs) (each location or site where syringe exchange takes place), 799 of which (51.2%) were in Catalonia and 66 (4.2%) in the Community of Madrid¹. Moreover, 664 pharmacies in Catalonia had an SEP, versus only 12 pharmacies in the Community of Madrid¹. Free syringes could be obtained only in the SEPs and there were no subsidised sales.

In other countries, SDs have been shown to improve access to sterile syringes in certain places or at certain times^4,5 although these informal resources are associated with a greater risk of HIV infection than the use of more structured programmes⁴. The extent of SEP coverage is critical to assuring their effectiveness⁶.

The aim of this work is to describe the differences in access to sterile syringes among injectors in Madrid and Barcelona and to study sterile syringe access as a predictor of safer injection practices that may prevent the transmission of bloodborne infections.

Materials and methods

The methodology used in the ITÍNERE cohort has previously been described in detail⁷. Independently of the social services, 991 young adults (18-30 years old) were recruited in the cities of Madrid, Barcelona and Seville between April 2001 and December 2003. All participants had used heroin on at least 12 days in the previous 12 months and on at least 1 day in the previous 3 months. The present analysis was restricted to the 465 participants from Madrid and Barcelona who had injected the drug in the previous 12 months and who answered three pre-coded questions: 1) Of all the sterile syringes you have used in the last 12 months, how many did you obtain free of charge? 2) From what kind of organization or service did you obtain the most free syringes in the last 12 months? 3) Where did you buy most of the syringes you purchased during this same time period? The 2.5% of injection drug users who did not respond were excluded. Their profile did not differ significantly from the rest of the population in terms of the main variables. The questionnaire⁷ was computer-assisted. Dried blood spot samples were also analysed (HIV, HCV).

The statistical significance of the differences was evaluated with the Chi square test for qualitative variables and by analysis of variance with subsequent comparisons with Scheffé's test for quantitative variables. Two dependent variables were explored separately in the logistic regression: «sharing» - injecting with used syringes or front/backloading (i.e., employing a used syringe to prepare the drug solution, which is then divided into one or more syringes for injection) and «reusing one's own syringes» - because these practices involve very different risks of transmitting infections and to avoid problems of co-linearity.

Most respondents were men (73.4%), born in Spain (84.9%), and without regular employment (69.2%); their mean age was 25.8 years (95% CI 25.5-26.1) and mean duration of injecting drug use was 6.5 years (95% CI 6.0-6.91). Some 86.5% had injected in the last 30 days. Injection in private places, such as flats or houses, was more frequent in Barcelona (19.3%) than in Madrid (11.4%), where it more often took place in open places (sites of drug sales or consumption, public squares, abandoned houses or similar places) (p < 0.05).

Only 4.2% (20) had not obtained any free sterile syringes in the last 12 months, 1.9% in Barcelona and 7.4% in Madrid (p < 0.01). These injectors differed from the rest of the sample in that they were more frequently women (45.0% vs. 25.8%; p=0.058) and sporadic users (61.1% vs. 22.8%; p < 0.001), and they less often injected in places where drugs are sold or consumed (10.0% vs. 63.8%; p < 0.001).

The way syringes were acquired - either all sterile syringes free of charge (ASSF) through SEPs or free plus purchased sterile syringes - was significantly associated with the city of residence. The proportion of drug users who obtained ASSF was smaller in Madrid than in Barcelona (table 1). In Barcelona, 62.8% obtained most of their free syringes from SEPs located in buses or vans, 20.5% from SEPs in pharmacies, 7.8% from SEPs at fixed locations, 5.7% through street-based social workers or educators and 3.1% in other ways. In Madrid, the respective percentages were 82.5%, 0.5%, 8.7%, 2.7% and 5.5% (p < 0.001). Of those who had purchased syringes in the 12 months before the interview (286), 51.7% had bought them primarily in pharmacies and 48% in the street (67% and 32.4%, respectively, in Barcelona, vs. 34.8% and 65.2% in Madrid, p < 0.001). Obtaining ASSF was also significantly and positively associated with being Spanish, not having a fixed abode, injecting drugs sporadically and not exhibiting most of the injection risk behaviour investigated.

After adjusting for city, sociodemographic variables (sex, age, country of birth, educational level, employment status and type of residence), frequency of injection, years of injection, HIV and HCV status, prostitution and way of obtaining sterile syringes, «not sharing» (not injecting with used syringes and not front/backloading in syringes used by others) was associated with obtaining ASSF (OR = 1.69; 95% CI 1.11-2.56) and sporadic injection (OR = 1.83; 95% CI 1.11-3.03). Not reusing one's own syringes was associated with the same variables (OR = 4.02; 95% CI 2.59-6.24; and OR = 2.50; 1.52-4.12, respectively) (table 2). Among those who purchased syringes, a significant association was seen between not reusing and buying most syringes in the street (OR = 1.85 95% CI 1.02-3.34). Not sharing was not associated with the way syringes were purchased.

Discussion

This is the first study of access to sterile syringes in a community sample of drug injectors in Spain. Free sterile syringes were found to be widely accessible in Madrid and Barcelona, which is consistent with the considerable increase in SEPs over the last 15 years^1,2. However, there are important differences between the two cities: a smaller proportion obtained ASSF in SEPs in Madrid, where those who purchased syringes most often bought them in the street. Both findings are consistent with the much larger number of EPs in Barcelona⁸ (141) than in Madrid (27-31; personal communication, Marta Franco) in 2003, and with the small number of pharmacies authorised for syringe exchange in the latter city¹. It is possible that the number of syringes provided by the SEPs per year to each injector was not less in Madrid, but that a substantial proportion of syringes reach users through SDs and thus are not free of charge. It may also be that the number of free sterile syringes put into circulation in Madrid was too low to meet the demand. Although it is not easy to estimate coverage when the number of users is unknown, NGOs and local governments should make an effort in this regard. Furthermore, a certain balance should be maintained between structured programmes and informal resources that do not focus on transmitting preventive messages, do not collect used syringes, and do not fully guarantee the sterility of injection material^4,9. It may be necessary to seek mechanisms to involve such a widespread resource as SDs in a structured way, as health agents.

In Madrid injection is more frequent in public or open places, and syringes are more often obtained in mobile SEPs. This seems consistent with the existence of a single vehicle-based programme in Barcelona, which in practice is used as a fixed site, and of public places where drugs are sold and consumed in many parts of Madrid. The characteristics of the illegal drug market and the needs of the injector should guide the types of SEPs to be developed, without forgetting that the characteristics or location of the programme may in some measure affect the choice of injection site.

It is logical that a smaller proportion of frequent injectors obtain ASSF; however, this could seriously limit the effectiveness of SEPs¹⁰, since those who inject more often have more opportunities to share injection material and to reuse their own. In fact, the regression analysis showed that those who inject fewer times, as well as those who obtain ASSF, have less risk behaviour (not sharing or not reusing). Frequent injectors need to have greater access to ASSF, particularly considering the high prevalence of different ways of sharing injection material^3,11 and the high incidence of HIV or HCV in injectors in both cities¹². Moreover, among those who buy syringes, access to SDs has a protective effect with regard to reuse of one's own syringes. However, this resource seems to have a limited capacity to prevent sharing of injection material, which would support a greater effect of SEPs as compared to informal resources for HIV prevention^4,9.

Acknowledgements

Our thanks to all the persons and institutions that helped with participant recruitment and follow-up and those that allowed us the use of their premises to conduct the interviews; to Marta Franco of the Agencia Antidroga of the Community of Madrid; and to all those who agreed to participate in ITÍNERE and formed part of the study sample.

References

1. Secretaría del Plan Nacional sobre el Sida. Informe del cuestionario de actividades de prevención (ICAP) por VIH/sida en las comunidades autónomas [edición electrónica] 2005. Madrid: Ministerio de Sanidad y Consumo; 2005. Disponible en http://www.msc.es/ciudadanos/enfLesiones/enfTransmisibles/sida/prevencion/informesAnualesCCAA.htm         [ Links ]

2. De la Fuente L, Bravo MJ, Barrio G, Parras F, Suárez M, Rodes A, et al. Lessons from the history of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic among Spanish drug injectors. Clin Infect Dis. 2003;37 Suppl 5:410-5.        [ Links ]

3. Bravo MJ, Royuela L, Barrio G, Rodríguez-Arenas MA, De la Fuente L. Prevalencia de prácticas indirectas de compartir material para inyectarse drogas en Galicia, Madrid, Sevilla y Valencia. Gac Sanit. 2004;18:472-8.        [ Links ]

4. Valente TW, Foreman RK, Junge B, Vlahov D. Needle-exchange participation, effectiveness, and policy: syringe relay, gender, and the paradox of public health. J Urban Health. 2001;78:340-9.        [ Links ]

5. Kuyper LM, Kerr T, Li K, Hogg RS, Tyndall MW, Montaner JS, et al. Factors associated with buying and selling syringes among injection drug users in a setting of one of North America's largest syringe exchange programs. Subst Use Misuse. 2006;41:883-99.        [ Links ]

6. Remis RS, Bruneau J, Hankins CA. Enough sterile syringes to prevent HIV transmission among injection drug users in Montreal? J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18 Suppl 1:57-9.        [ Links ]

7. De la Fuente L, Brugal MT, Ballesta R, Bravo MJ, Barrio G, Domingo-Salvany A, et al. Metodología del estudio de cohortes del proyecto Itínere sobre consumidores de heroína en tres ciudades españolas y características básicas de los participantes. Rev Esp Salud Pública. 2006;20:475-91.        [ Links ]

8. Brugal T, Bravo MJ, Vallés N, Díaz de Quijano, Fabregat A, Ambrós M. Formas de obtención de jeringas en los jóvenes inyectores de Madrid y Barcelona y su relación con la conducta de inyectarse con jeringas usadas. Bilbao: VII Congreso Nacional sobre el Sida, Mayo 2003. Pub. Of. SEISIDA. 2003;14:152.        [ Links ]

9. Latkin CA, Forman VL. Patterns of needle acquisition and sociobehavioral correlates of needle exchange program attendance in Baltimore, Maryland, USA. J Acquir Immune Defic Syndr. 2001;27:398-404.        [ Links ]

10. Strathdee SA, Patrick DM, Currie SL, Cornelisse PG, Rekart ML, Montaner JS, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997;11:59F-65F.        [ Links ]

11. Folch C, Merono M, Casabona J. Factores asociados a la práctica de compartir jeringas usadas entre usuarios de droga por vía parenteral reclutados en la calle. Med Clin (Barc). 2006;127:526-32.        [ Links ]

12. Vallejo F, Toro C, Brugal MT, De la Fuente L, Soriano V, Jiménez R, Ballesta R, Bravo MJ. Muy alta incidencia de VIH y VHC en jóvenes consumidores de heroína. Logroño: XXIV Reunión Científica Anual de la Sociedad Española de Epidemiología, octubre 2006. Gac Sanit. 2006;20 Supl SEE: 130.        [ Links ]

Correspondence: ]]> Luis de la Fuente.
Centro Nacional de Epidemiología.
Instituto de Salud Carlos III. Madrid.
Sinesio Delgado 6. 28029 Madrid. Spain.
E-mail: mbravop@isciii.es

Received: 6 October 2006.
Accepted: 12 June 2007.